Navigation Links
Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Date:11/12/2009

BASKING RIDGE, N.J., Nov. 12 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, November 17 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. This conference is well attended and will include several hundred institutional investors with more than one hundred healthcare management teams presenting.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , on the ... in this country, testified on behalf of House Bill ... in the nation to consider creating a clearinghouse to connect ... to receive them. , Infertility affects over 7.3 million couples ... of the few medical diseases that is curable, the treatment ...
(Date:4/27/2015)... 27, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the year ended December 31, 2014. ... dollars and presented under International Financial Reporting Standards ... results did not provide the outcome management and ... remain at iCo Therapeutics", said Andrew Rae ...
(Date:4/27/2015)...  Edico Genome today announced that collaborative data ... Stanford Universities showed the DRAGEN™ Bio-IT Processor sped ... depth of coverage by tenfold, generating results in ... standard software. "Processing large amounts of ... research and clinical labs, in terms of the ...
(Date:4/27/2015)... , April 27, 2015 ... this release, please scroll to bottom . ... equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX ), ... Pharmaceuticals Corporation (NASDAQ: SNTA ), Spectrum Pharmaceuticals ... (NASDAQ: MDVN ). Free research report on ...
Breaking Biology Technology:Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5
... Administration (FDA) issued in July 2007 its Nanotechnology Task ... could be used in most product types regulated by ... by the fact that properties relevant to product safety ... nanoscale. , Anticipating the potential for rapid commercialization ...
... is only valuable if we possess it in large-sized ... case for those interested in exploiting gold,s exceptional ability ... the oxidation of poisonous carbon monoxide (CO) into harmless ... could potentially improve the effectiveness of catalytic converters that ...
... 5 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today ... Healthcare Unplugged Conference on Tuesday, September 9,2008 at approximately ... webcast live and may be accessed through a link ... . The webcast,will be available for 30 days following ...
Cached Biology Technology:Nanotechnology and the FDA: size matters 2NIST and partners identify tiny gold clusters as top-notch catalysts 2Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... United Nations meeting emphasized nutrition as critical to producing ... Clinton said a key focus is helping farmers grow ... experts say getting back to basics by eating balanced ... in many ways. As fall approaches, Robin ...
... S.R.Varadhan, a professor at New York University,s Courant Institute ... the National Medal of Science, the highest honor bestowed ... Varadhan and the six other recipients of this year,s ... a White House ceremony later this year. Varadhan, ...
... is available in Spanish . U.S. Department ... (UAVs), a tool used by the military, may be suitable ... tracts of western rangeland. Ranchers, government agencies and private ... see how they are being altered by floods, forest fires ...
Cached Biology News:Eating balanced meals, farm-fresh produce benefits families, communities, nutrition researchers say 2NYU mathematician Varadhan named recipient of National Medal of Science 2A labor saving way to monitor vast rangelands 2
... DNA Ligase catalyzes the formation of phosphodiester ... double-stranded DNAs with 3' hydroxyl and 5' ... buffer optimizes ligation which can be performed ... are not substrates for this enzyme. ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... is a major step forward in ... handling system - with one universal ... modules. All five single channel and ... one handle. The lightweight handle is ...
Sulfadimethoxine (CH-2027)...
Biology Products: